Navigation Links
Dendreon Announces Closing of Registered Direct Offering
Date:4/8/2008

SEATTLE, April 8, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the previously announced registered direct offering of 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock. Net proceeds received by Dendreon were approximately $46 million. Lazard Capital Markets LLC served as sole placement agent for the offering.

The offering is being made pursuant to previously effective shelf registration statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... Sept. 15, 2014 Zymo Research Corp., has ... solution for safe ambient temperature storage and transport ... the infectivity of agents in such samples is ... integrity of the viral nucleic acids for subsequent ... Ebola epidemic in West Africa ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2
... programs for the University of Wisconsin-Madison, is part information technologist, ... Part II of this interview. In Part I , ... (below), he addresses creating a culture of innovation and finding ... featured speaker at the Fusion 2007 CEO-CIO Symposium . ...
... In a move that could bring additional investment partners to ... an office in Ann Arbor, Mich. after receiving money from ... which recently moved into a larger space in the MGE ... of three venture firms selected to receive funding through a ...
... - Oskar Anderson, chief information officer for the Wisconsin ... succeed Matt Miszewski as administrator of the state Division ... this week, will join the Department of Administration ... His appointment was confirmed this morning in an e-mail to ...
Cached Biology Technology:Venture Investors to open Michigan office 2Oskar Anderson to succeed Miszewski as head of state technology division 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... research team from Rollins College in Florida and the University ... the coral-killing pathogen that causes white pox disease of Caribbean ... elkhorn coral was listed for protection under the United States ... disease. The team,s findings have just been published in the ...
... A recent study demonstrated increased rates of celiac disease ... in the May-June 2011 issue of The Journal ... patients presenting with infertility. Each participant underwent serologic ... testing. The 4 patients who had positive serum ...
... , Cincinnati, (OH) - The International Rett Syndrome Foundation ... to support eight cutting-edge projects that aim to accelerate ... IRSF is the world,s largest private source of funding ... 1998, IRSF has cumulatively funded over $24M in high ...
Cached Biology News:Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3IRSF awards over $650,000 for Translational Rett Syndrome research 2
... PP1, purified Formulation: 0.15M NaCl, ... 0.1mM MnCl2, 1mM MgCl2, 1mM EGTA, ... dephosphorylation of proteins Purification: DEAE chromatography, ... and gel filtration chromatography Quality Assurance: ...
... Endothelin-1 (human, porcine) Endogenous potent ... ETA receptor and modulates vascular tonus. ET-1, ... three distinct endothelin genes. ET-2 and ET-3 ... two and six amino acids, respectively. All ...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: